Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Share buyback programme update

26 Jun 2025 16:19

RNS Number : 6278O
IP Group PLC
26 June 2025
 

FOR RELEASE ON

26 June 2025

 

 

IP Group plc - Share buyback programme update

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to provide the following update.

In line with its previously announced intention, the Group is now allocating all of the proceeds it has received to date from the secondary sale announced on 09 December 2024 together with 50% of the Group's other realisations received in 2025, being £20m in aggregate, towards its buyback programme (the "Buyback Programme"). The Buyback Programme will therefore today be extended by £20m to a total of £75m (the "Buyback Extension").

The Buyback Extension will run until 31 December 2025 unless completed or terminated earlier, or unless the Company and Deutsche Numis agree otherwise (in which event an announcement would be made).

Since commencing the Buyback Programme, the Group has purchased 122,904,597 shares at an average price of 44.8 pence per share for an aggregate consideration of £55m. All shares acquired under the Buyback Programme have been, or will shortly be, cancelled. Following such cancellation, the Company's issued share capital consists of 918,491,679 Ordinary Shares with voting rights and there are no Ordinary Shares held in treasury.

Details of the Buyback Extension

 

For the Buyback Extension, IP Group has entered into a non-discretionary agreement with Deutsche Numis to continue to manage the Buyback Programme on its behalf. Deutsche Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group.

Any Ordinary Shares purchased under the Buyback Extension will be cancelled.

The Buyback Extension is in accordance with IP Group's general authority to purchase a maximum of 141,415,378 Ordinary Shares granted by its shareholders at the Annual General Meeting held on 12 June 2025. The Buyback Programme will continue to be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019), and in accordance with Chapter 9 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it is not in a closed period and currently has no other unpublished price sensitive information.

Save to the extent they are varied by this announcement, all other parameters outlined in the Company's announcement on 18 December 2023 will continue to apply.

IP Group will continue to make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Alex Donaldson

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutionsOur specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPKABDPBKDFAB
Date   Source Headline
15th Jan 20253:21 pmRNSForm 8.3 - Tissue Regenix Group plc
15th Jan 20257:00 amRNSTransaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
10th Jan 20256:02 pmRNSTransaction in Own Shares
10th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20257:00 amRNSShare buyback programme update
8th Jan 20257:00 amRNSTransaction in Own Shares
6th Jan 20255:43 pmRNSTransaction in Own Shares
31st Dec 20247:00 amRNSTotal Voting Rights
20th Dec 20245:09 pmRNSTransaction in Own Shares
20th Dec 20241:46 pmRNSForm 8.3 - Intelligent Ultrasound Group plc
20th Dec 20247:00 amRNS-RTwo life sciences companies receive cash offers
20th Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20241:10 pmRNS£119m initial cash after sale of Featurespace
18th Dec 20246:26 pmRNSTransaction in Own Shares
18th Dec 20247:00 amRNSTransaction in Own Shares
16th Dec 20244:55 pmRNSTransaction in Own Shares
13th Dec 20245:59 pmRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
12th Dec 20247:00 amRNSAGM post-meeting shareholder engagement update
12th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
9th Dec 20242:44 pmRNSHolding(s) in Company
9th Dec 202412:00 pmRNSHolding(s) in Company
9th Dec 20247:00 amRNSSecondary sale of minority holdings in portfolio
6th Dec 20245:13 pmRNSTransaction in Own Shares
6th Dec 20241:57 pmRNSForm 8.3 - Tissue Regenix Group plc
6th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20245:18 pmRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20241:35 pmRNSHolding(s) in Company
2nd Dec 20247:01 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20246:16 pmRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
25th Nov 20246:09 pmRNSTransaction in Own Shares
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
21st Nov 20247:00 amRNSTransaction in Own Shares
20th Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20245:59 pmRNSTransaction in Own Shares
15th Nov 20248:45 amRNSForm 8.3 - Tissue Regenix Group plc
15th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20245:10 pmRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20245:17 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.